This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Detlev Mennerich
SVP, Global Head of Business Development & Licensing at Boehringer Ingelheim


  • Detlev studied chemistry in Braunschweig and Bordeaux and holds a PhD in Cell & Molecular Biology.
  • In 2001, he started his industrial career at metaGen Pharmaceuticals and Schering AG in Berlin as a Scientist in Oncogenomics focusing on target validation and biomarker research.
  • In 2005, he joined Boehringer Ingelheim in Biberach an der Riss, where he held several positions with increasing responsibility: he started as Laboratory Head in Genomics for new drug concept nominations. In 2009, Detlev moved to Ridgefield, CT (USA) as Project Leader for an anti-inflammatory antibody project (Spesolimab, which has been submitted for market authorization in 4Q/2021). In 2011, he returned to Biberach heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation.
  • Beginning of 2014, he started as investment director at the Boehringer Ingelheim Venture Fund investing in clinical translation of pioneering therapeutic approaches, i.e., in the field of immuno-oncology, immuno-tolerization and regenerative concepts. He served as Board Member of ViraTherapeutics GmbH in Innsbruck, until ist acquisition by Boehringer Ingelheim in September 2018. He also served as Board Member of NBE Therapeutics AG in Basel, until its acquisition by Boehringer Ingelheim in January 2021.
  • In 2020, Detlev returned to internal Discovery Research unit as Global Head of Research Beyond Borders, before he moved in 2022 into his current role as Global Head of Business development & Licensing for Boehringer Ingelheim.

Agenda Sessions

  • Navigating the changing pharmaceutical dealmaking landscape